Top Glove Corporation Bhd (Top Glove) is making a strong comeback in the U.S. market, regaining momentum that could help reverse the sluggish glove sector sentiment. According to Kenanga Research’s latest update, the glove maker is seeing a surge in U.S. orders, now accounting for 30% of total volume — and it's aiming for 40% within two years.
Despite global trade headwinds and tariff-related uncertainties, Top Glove is expected to post double-digit sales growth in 4QFY25, thanks to recovering U.S. demand. This comes as its plant utilization rate climbs to 65%, up from 61% last quarter.
Outlook: Positive Momentum Building
Sales Volume Growth: Targeting a 15% quarter-on-quarter growth in 4QFY25.
U.S. Pricing Edge: Despite recent reciprocal tariffs, Malaysian gloves remain 10–30% cheaper than Chinese counterparts in the U.S. market.
Production Ramp-Up: The extra 300 million pieces per month could boost quarterly revenue by RM70 million.
ASP Pressure Easing: A clearer view of U.S. tariff policies could trigger higher ASP (average selling price), improving margins.
Risks to Watch
Aggressive pricing from Chinese players via Indonesian facilities (which enjoy a lower 19% U.S. tariff) could weigh on Malaysian players.
Potential changes in tariff structures could alter the playing field.
A prolonged price war could pressure margins if rivals continue to sell below cost.
Investment Call: OUTPERFORM
Kenanga maintains its Target Price (TP) of RM0.93, based on 1.6x FY26F BVPS. At the current price of RM0.70, the stock is trading at a deep discount — 2 standard deviations below its 1-year forward average.
For investors looking for a rebound play in the glove sector, Top Glove presents an interesting case: higher U.S. demand, improving utilization, and pricing resilience. As global healthcare demand normalizes post-pandemic, Top Glove could regain footing as a global market leader.
Comments
Post a Comment